Skip to main content

Table 2 Details of irAEs that occurred among the patients

From: Predictive biomarkers for immune-related adverse events in cancer patients treated with immune-checkpoint inhibitors

Grade of irAEs

Number of patients (%)

Grade 1

87 (20.8%)

Grade 2

75 (17.9%)

Grade 3

7 (1.7%)

Grade 4

7 (1.7%)

IrAEs category

 

Pneumonia

38 (9.1%)

Thyroiditis, hypothyroidism, hyperthyroidism

38 (9.1%)

Cardiovascular toxicity

34 (8.1%)

Dermatologic toxicity

29 (6.9%)

Hepatitis

17 (4.1%)

Diarrhea, colitis

5 (1.2%)

Hyponatremia

3 (0.7%)

Oral mucositis

2 (0.5%)

Adrenal insufficiency

2 (0.5%)

Nephritis

2 (0.5%)

Diabetes mellitus

2 (0.5%)

Encephalitis

1 (0.2%)

Myathenia gravis

1 (0.2%)

Hemolysis

1 (0.2%)

Hypopituitarism

1 (0.2%)

Total patients irAEs

176 (42.1%)